Altre lingue Ceapro Inc.

Azioni

CZO

CA1499071076

Mercato chiuso - Toronto S.E. Altri mercati azionari 21:16:26 06/05/2024			Variaz. 5gg	Var. 1 gen.
0,245 ^CAD	0,00%		-5,77%	+28,95%

29/04	Ceapro Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
29/04	Ceapro Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	29/04
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights	29/04
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28/03
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28/03
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris	28/03
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27/03
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	12/03
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings	12/03
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	26/02
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	26/02
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company	26/02
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business	23/02
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris	15/02
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro	15/02
Canadian Investment Regulatory Organization Trade Resumption - CZO	14/12
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	14/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Ceapro Inc.

Azioni

CZO

CA1499071076

Altre lingue

Filtri